Erschienen in:
14.01.2020 | Original Article
A20-OVA Nanoparticles Inhibit Allergic Asthma in a Murine Model
verfasst von:
Xiang-Qian Luo, Jian-Wen Zhong, Shu-Yao Qiu, Min Zhi, Li-Qiang Yang, Yi-Long Zhou, Fen-Xuan Zhou, Ping-Chang Yang, Da-Bo Liu, Li-Hua Mo
Erschienen in:
Inflammation
|
Ausgabe 3/2020
Einloggen, um Zugang zu erhalten
Abstract
The skewed T helper (Th) 2 response plays a critical role in the pathogenesis of allergic asthma. Regulatory T (Treg) cells and the regulatory cytokines are required in maintaining the homeostasis in the body. This study aims to determine the effects of a poly(lactic-co-glycolic) acid (PLGA)-ovalbumin (OVA)+A20 (a ubiquitin E3 ligase) nanovaccine on inhibiting allergic asthma in a murine model. In this study, A20 and OVA (a model antigen) were encapsulated into PLGA to be a nanovaccine (PLGA-OVA+A20). An allergic asthma murine model was developed with OVA as the specific antigen to test the role of PLGA-OVA+A20 nanovaccine in maintaining the immune homeostasis in the airway tissues. The results showed that PLGA-OVA+A20 nanovaccine inhibited the asthma responses in mice by suppressing Th2 inflammatory responses, promoting the generation of Treg cells in the airway tissues. We conclude that the PLGA-OVA+A20 nanovaccine has a marked inhibitory effect on the airway allergic response in sensitized mice by significantly promoting the generation of Treg cell and IL-10. The data suggest that PLGA-OVA+A20 has translational potential in the treatment of allergic asthma.